Status:
TERMINATED
[S,S]-Reboxetine Add-On Trial
Lead Sponsor:
Pfizer
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of adjunctive treatment of pregabalin with \[S,S\]-Reboxetine against pregabalin monotherapy in patients with PHN
Eligibility Criteria
Inclusion
- Patients must have pain present for more than 3 months after the healing of shingles skin rash
- Patients at screening must have a score \>/=40 mm on the pain visual analogue scale
Exclusion
- Patients with significant renal and hepatic impairment
- Patients with other severe pain, that may impair the self-assessment of the pain due to shingles
- Patients with clinically abnormal electrocardiogram
Key Trial Info
Start Date :
August 22 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 11 2007
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT00334685
Start Date
August 22 2006
End Date
October 11 2007
Last Update
December 16 2019
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
2
Pfizer Investigational Site
Gilbert, Arizona, United States, 85234
3
Pfizer Investigational Site
North Dartmouth, Massachusetts, United States, 02747
4
Pfizer Investigational Site
St Louis, Missouri, United States, 63141